WO2004105734A1 - Procede de preparation de microcapsules - Google Patents

Procede de preparation de microcapsules Download PDF

Info

Publication number
WO2004105734A1
WO2004105734A1 PCT/CA2004/000803 CA2004000803W WO2004105734A1 WO 2004105734 A1 WO2004105734 A1 WO 2004105734A1 CA 2004000803 W CA2004000803 W CA 2004000803W WO 2004105734 A1 WO2004105734 A1 WO 2004105734A1
Authority
WO
WIPO (PCT)
Prior art keywords
microcapsule
particle
particles
microns
coating
Prior art date
Application number
PCT/CA2004/000803
Other languages
English (en)
Inventor
Patrice Hildgen
Jean-Michel Rabanel
Philippe Mercier
Original Assignee
Valorisation Recherche, Societe En Commandite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valorisation Recherche, Societe En Commandite filed Critical Valorisation Recherche, Societe En Commandite
Publication of WO2004105734A1 publication Critical patent/WO2004105734A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Definitions

  • the present invention relates to a method of preparing permeable and sized microcapsules having suitable mass transfer capabilities. More precisely, the present invention relates to a method of preparing permeable and sized microcapsules having suitable mass transfer capabilities, wherein a polymeric degradable particle is first prepared, then coated with a particular coating mixture, and finally selectively degrading the coated particle obtained in the previous step so as to form a microcapsule containing a cavity.
  • the so obtained microcapsule may optionally be loaded with biologically active ingredients and may be used for cell encapsulation or as drug delivery system.
  • Immuno- isolation also allows for the use of animal cells lines, known as xenotransplantation, and immortalized cell lines, eventually genetically modified, instead of primary human cell lines.
  • the active molecule can be continuously secreted or in response to host stimulus, for example glucose concentration for encapsulated pancreatic islets.
  • Other advantages of encapsulation consist in the possibility to target specific organ or body compartments, thus minimizing systemic dosage and potential side effects.
  • the capsule can be considered as a "niche", a cell friendly microenvironment with the presence of an extra-cellular matrix, which can serve as cell scaffold. The use of such a capsule can also prevent excessive cell growth and eventually allow for the removal of the cells if problems arise during the course of treatment.
  • Macroscopic devices (more than 1 ,5 mm) are usually implanted by surgical procedures (idem. Uludag et al. (2000)). Macrocapsules are usually formed with synthetic co-polymers such as: polyacrylonitrile-polyvinyl chloride (PAN-PVC), polyethersuflone (PES), poly-tetra-fluoro-ethylene (PTFE) or polypropylene (PP) for greater stability (Advanced Drug Delivery Reviews, 33, (1 998), pp. 87-1 09, Li, R.H.). These devices are known for their stability, high loading capacity and retrievability, though a problem associated with them consists in that mass transfer is not optimal.
  • PAN-PVC polyacrylonitrile-polyvinyl chloride
  • PES polyethersuflone
  • PTFE poly-tetra-fluoro-ethylene
  • PP polypropylene
  • Fibrous tissue deposition is frequent and the size of the device makes implantation invasive and lowers a patient comfort. Moreover, the constant need for surgical procedures can impose a recurrent risk of infection.
  • micro-encapsulation systems under the 1 mm range have been described in earlier works, such as in the scientific journals entitled: Sciences, 146, (1 964), pp. 524-525 (Chang T.G.) and Science, 210, (1 980), pp. 908- 910 (Lim F., et al.). Most of these micro-encapsulation systems rely mainly either on gentle hydrogel cell embedding or synthetic membrane formation by co-extrusion of a cell preparation and capsule material.
  • Natural polyelectrolyte polymers such as alginates can form gel when in contact with electrolytes of opposite charge such as cations, namely Ca 2+ , Ba 2+ or poly-L-Lysine, and they can form capsules by emulsification or extrusion (see Science, 210, (1 980), pp. 908-91 0 (Lim F., et al.)).
  • synthetic hydrogel polymers such as polyphosphazene, or blends of polymethacrylates have been proposed as well as the combination of natural and synthetic polymers. Use of agarose, forming gel upon heating, has been described for bead preparation.
  • micro-encapsulation mass transfer of various products such as molecules secreted by encapsulated cells, nutriments, drugs or products of enzymatic reactions, is optimized (high surface/internal volume ratio); thus increasing cell viability and allowing a faster secretory response to an external signal.
  • a micro-encapsulation technique also has its limitations. These limitations include mechanical fragility and instability of ionic interactions in hydrogels and batch-to-batch variability, which leads to differences in permeability properties. This is particularly the case for natural hydrogels, wherein such materials entail problems of variable biocompatibility of materials, limited cell loading capacity, stress on cells during encapsulation procedures and non homogenous repartition of cell in beads which could eventually lead to host immunological responses.
  • Other limitations are further described in an scientific article entitled “Engineering challenges in cell- encapsulation technology", Trends in Biotechnologies, 14, (1996), pp. 158- 161 (Colton C.K.).
  • International publication no. WO 02/05943 A1 distinguishes itself from the present application in that it describes a process for preparing a gas during amylopectin reticulation by bubbling.
  • the so described process is very different from the one described in the present invention, namely in that it does not suggest or disclose the possibility that active ingredients can be incorporated in the polymeric degradable particle.
  • the process defined in the aforementioned international publication does not work. Indeed, the only feature that seems to work in this International publication is automatic cell injection. Few methods have been described to prepare hollow particles in the micrometer and millimeter range and which are compatible with cell viability.
  • a first object of the invention is to satisfy the above needs.
  • the invention provides a process for preparing a permeable and sized microcapsule having suitable mass transfer capabilities, said method comprising the step of: a) preparing a polymeric degradable particle and optionally loading it with an active ingredient. b) coating said polymeric degradable particle obtained in step a) with a coating mixture by emulsion polymerization, thus forming a coated particle of desired thickness; and c) selectively degrading the coated particle obtained in step b), in either basic or acidic conditions, by a pH change and/or hydrolytic degradation so as to form at least one sized cavity inside said coated particle.
  • An advantage with the above-mentioned method for preparing microcapsules resides in that the size of the cavity can be varied. Indeed, other components such is size, morphology and porosity of the particle may also be changed.
  • a second object of the invention lies in a permeable and sized microcapsule having suitable mass transfer capabilities as obtained by the method mentioned hereinabove.
  • a third object of the invention lies in the use of a permeable and sized microcapsule having suitable mass transfer capabilities as prepared by the method as defined hereinabove for cell encapsulation, for the preparation of microreactors and/or microreservoirs, and the preparation of multi- compartmental capsules.
  • FIG. 1 is a schematic illustration of the products obtained during the steps of the method for preparing microcapsules according to the present invention.
  • step (1 ) represents a polymeric degradable particle that has been prepared in this step
  • step (2) represents the polymeric degradable particle that is obtained after coating in step 2
  • step (3) represents the so coated polymeric degradable particle after it has been subjected to selective degradation to form a cavity therein
  • step (4) represents the microcapsule loaded with cells and/or active ingredients.
  • FIGS. 1 are illustrations of microcapsules obtained by the method according to the present invention: A) Core particles containing amylopectin particles crosslinked with 10% (w/w) trimetaphosphate (TMP), stained with chromium oxide powder, size: 250-355 micron (in 0.05 M NaOH); B) idem particle obtained after coating with an amylopectin gel crosslinked with epichlorohydrin (particles sieved: 425-500 microns); C) core particle subjected to selective degradation, assay: incubation, NaOH 1 N/37°C/48 hours, core particles are stained with methylene blue. Bar represents 0.500 mm.
  • Figure 3 are illustrations of the PLGA core particles after they have been subjected to the steps of coating and selective degradation according to a preferred embodiment of the invention (Assay PGE0003).
  • Figure 4 are illustrations of particles when they have been subjected to the step of coating according to the present invention and the effect of Span 80TM therein.
  • Figure 5 are illustrations of particles when subjected to the coating according to a preferred embodiment of the present invention and the effect of polyethylene glycol distearate (PEGDS) and viscosity thereon.
  • Figure 6 are illustrations of core particles after having been subjected to the step of coating according to a preferred embodiment of the present invention.
  • Figure 7 are illustrations of microcapsules obtained by the method according to the present invention. The illustrations are by a SEM.
  • Control amylo-pectin gel particle Assay C001 :
  • Figure 8 are illustrations of microcapsules obtained by the present invention and depicting the release of fluorescent markers.
  • Figure 9 is a graph demonstrating the diffusion of fluorescent markers.
  • Figure 1 1 are illustrations of microcapsules obtained by the method according to the present invention, which are to preferably be used as a microreservoir ( Figure 1 1 A) or a microreactor ( Figure 1 1 B).
  • core particle and “template particle” may be used to define the “polymeric degradable particle” as used in the appended claims.
  • mass transfer as defined by the IUPAC Compendium of chemical terminology, relates to a “spontaneous process of transfer of mass across non-homogeneous fields.
  • the driving force can be difference in concentration (i.e. diffusion gradient) or partial pressure of the component.”
  • the expression “mass transfer” may also relate to the diffusion of substances that could either penetrate inside the microcapsule, for example gas, nutriments, reactive agents, etc., or get out of the microcapsule, for example via secretion.
  • the object of the present invention is to provide a method of preparing a permeable and sized microcapsule having suitable mass transfer capabilities.
  • This method comprises the steps of: a) preparing a polymeric degradable particle and optionally loading it with an active ingredient, b) coating said polymeric degradable particle obtained in step a) with a coating mixture by emulsion polymerization, thus forming a coated particle of desired thickness; and c) selectively degrading the coated particle obtained in step b), in either basic or acidic conditions, by a pH change and/or hydrolytic degradation so as to form at least one sized cavity inside said coated particle.
  • a polymeric degradable particle is prepared.
  • a polymeric degradable particle can be prepared by various techniques known to a person skilled in the art.
  • polymers that can be used as choice of polymeric degradable particle according to the present invention include, but is not limited to: polyesters, polyanhydrides, polyamides, polyorthoesters, polyacrylcyanides, polylactide, poly(lactide-co- glycolide), polycaprolactone, polyhydroxybutyrate, their copolymers and mixtures thereof.
  • polyesters polyanhydrides, polyamides, polyorthoesters, polyacrylcyanides, polylactide, poly(lactide-co- glycolide), polycaprolactone, polyhydroxybutyrate, their copolymers and mixtures thereof.
  • suitable polymers and combinations thereof which can be used as choice of polymeric degradable polymer particle.
  • the polymeric degradable particle such as PLA and/or PLGA
  • the Applicant can prepare a coated particle of desired thickness.
  • this step comprises coating of the polymeric degradable particle obtained in the preceding section.
  • a natural polysaccharide such as an amylopectin is dissolved in a NaOH solution under stirring so as to form a solution.
  • epichlorohydrin and/or another crosslinking agent known to a person skilled in the art is then added to this solution, thus forming a coating mixture.
  • the polymeric degradable particles being treated for example by sieving, are then added to the aforementioned coating mixture and is preferably incubated for a few minutes.
  • the viscous mixture is then preferably introduced into paraffin oil under stirring.
  • the solution can further contain a surfactant, though such is not necessarily required.
  • paraffin oil can by replaced by another type of oil such as silicone oil.
  • paraffin oil is preferred since it is non-toxic and inert.
  • introduction of the viscous mixture into the paraffin oil can be done by a direct transfer or by injection.
  • suitable types of polysaccharides may include and is not limited to starches, modified starches, alginate, amylopectin, cellulose, amylose, chitosan, xanthan and other modified celluloses. There, of course, exist other types of natural polysaccharides that may be considered.
  • the crosslinking agent used in step b) may include trimetaphosphate, epichlorohydrin and other chemical compounds that are accepted by the FDA standards.
  • reticulating agents such as: dichlorodiethyl ether; dibasic/tribasic carboxylic acid (both carboxyl etherify OH groups); anhydrides (acetic); divinyl sulfone; diepoxides; cyanuric chloride; di-isocyanates; 1 ,6-hexanedibromide; N,N methylenebisacrylamide; esters of propynoic acid; imidazolium salts of polybasic carboxylic acids; aldehydes such as formaldehyde, acetaldehyde, dialdehyde, glutaraldehyde (toxic); and N,N-(3-dimethylaminopropyl)-N-ethyl carbodiimide (EDC), may be used.
  • the coated particle obtained in step b) preferably has a thickness of about 75 to 100 microns.
  • the thickness could preferably be from 500 nm to 500 microns.
  • the coated particle obtained in section B) is selectively degraded, in either basic or acidic conditions, by a pH change and/or hydrolytic degradation so as to form a sized cavity inside the coated particle.
  • reaction wherein one changes pH of a medium and/or hydrolytic degradation is quite well known to a person skilled in the Art.
  • it is beneficial to use such a step in that it allows the Applicant to selectively adjust the size of the cavity in the coated particle, in either basic or acidic conditions, thus allowing the microcapsule to contain foreign matter.
  • microcapsule it is at this stage in the method of preparing a permeable and sized microcapsule having suitable mass transfer capabilities, is that one can modify the nature of the microcapsule. For example, one can:
  • microcapsules obtained by the method according to the present invention will depend on the applications considered.
  • a microcapsule with one or more compartments can be used for the insertion of cells into an artificial organ application or in a biotechnological application.
  • Microcapsules can also be used as a microreservoir system, which is able to liberate drugs at a constant drug rate.
  • the drug can be a protein, genetic material, a peptide and/or small molecules.
  • suitable drugs may include and are not limited to: plasmids for gene therapy, proteins (i.e. deficient enzymes, G-CSF, erythropectin, growth hormones, FSH and the like), and those known to person skilled in the art to have low biodisponibility or stability problems.
  • proteins i.e. deficient enzymes, G-CSF, erythropectin, growth hormones, FSH and the like
  • drugs may include: omeprazole, enanapril and the like.
  • microcapsules obtained by the method according to the present invention can also be used as a drug delivery system. It is worth mentioning that in the application of oral drug delivery, the goal of the microcapsule is to increase the biodisponibility of the drug. This goal can be achieved since the coating of the microcapsule acts as a mucoadhesive agent.
  • the surface of the microcapsule becomes porous.
  • the microcapsules containing one or more cavities; thus being multi-compartmental may also contain a reactive material. Indeed, when the microcapsule erodes, the reactive material can diffuse into a cavity where a reaction can occur and form an active material, such as NO. It is worth mentioning that the active material can also diffuse outside of the microcapsule. In fact, the control of drug release is obtained by the porosity and pore size of the microcapsule. Preferably, the release rate is a near zero order mechanism.
  • the mean size of core particle obtained from the above- mentioned techniques is preferably from 500 nanometers to 500 micrometers.
  • microcapsule obtained by the method according to the present invention can also be used as a micro- reactor.
  • Polylactide was prepared in the laboratory. Briefly, a catalyst such as tetraphenyl tin (Aldrich) was mixed with a precursor 3,6-dimethyl-1 ,4- dioxane-2,5-dione (Aldrich) in a 1 /10 000 proportion (w/w) and introduced in a round bottom flask under a continuous flush of an inert gas such as argon. Preferably, the flask was heated at 180°C for 3 hours. By-products were dissolved in acetone and precipitated in water. The polymer was dried and freeze-dried.
  • a catalyst such as tetraphenyl tin (Aldrich) was mixed with a precursor 3,6-dimethyl-1 ,4- dioxane-2,5-dione (Aldrich) in a 1 /10 000 proportion (w/w) and introduced in a round bottom flask under a continuous flush of an inert gas such as argon. Pre
  • Polylactide-co-glycolide (PLGA) was from Boehringer- Ingelheim (RG 504H, 50:50 lactide/glycolide) with a Mw of 48 000, partially hydrolysed amylopectin (Glucidex 2) was from Roquette (France); paraffin oil, Epichlorohydrin and Span 80TM were from Fluka; fluorescein isothiocynate (FITC) dextrans, trimetaphosphate (TMP), sodium carbonate and polyethylene glycol distearate (PEGDS) were from Sigma, organic solvents were from Laboratoire MAT (Montreal), partially hydrolyzed polyvinyl alcohol (9-10000 PM) was from Aldrich.
  • SEC Size Exclusion Chromatography
  • trimetaphosphate and 20 g of amylopectin were stirred in 36 ml of H 2 O for 2 hours. 4 ml of sodium carbonate was added and the preparation was incubated for 90 minutes at 42°C with frequent agitation. The preparation was transferred slowly into 600 ml of paraffin oil under stirring (750 rpm, Caframo mixer) overnight at 25°C. Water was added and after sedimentation, the particles were washed, re-dispersed in 0,05 M NaCI and sieved. Coating of amylo-pectin core particles
  • amylopectin was dissolved in 6 ml of NaOH (2N).
  • epichlorohydrin ratio: 1 mole per 1 ,5 mole of sugar monomer
  • 10g of core particles are mixed and transferred into 600 ml of paraffin oil under stirring (500 rpm, Caframo mixer) for 6 hours. Particles were then recovered by sedimentation in water, sieved (mesh sizes: 150, 355, 425 and 710 microns) and washed to remove salts, traces of oil and epichlorohydrin.
  • PLA and PLGA core particles were prepared according to the solvent extraction-evaporation technique. Typically, 500mg of PLGA or PLA were dissolved in 3,5 ml of chloroform and injected in 250 ml of 0,3% PVA (w/v) and kept under stirring for 12 hours (Caframo stirrer). Particles were then collected, sieved (sieves: 150 and 350 microns) and washed before coating. Viscosity of the polyester solution in solvent (5-20% w/v) and stirring speed (150 to 350 rpm) were adjusted for desired particle size.
  • amylopectin Glucidex 2
  • 2,5 to 7 ml of NaOH (2N) for one hour under stirring.
  • epichlorohydrin was added in a ratio of 1 /1 ,5 or 1 /9 (ratio mole of epichlorohydrin per mole of sugar monomer).
  • Sieved core polyester particles were added and incubated under stirring for 1 to 5 minutes.
  • the viscous mixture was then introduced in 400 to 800 ml of paraffin oil under stirring (straight blade or Rushton propeller, at a speed of 250 to 900rpm, Caframo stirrer) in the presence of surfactant Span 80TM (from 0% to 0,5% vol.
  • the surfactant is only a preferred embodiment of the invention. Indeed, the preferred introduction of the surfactant can be either done by direct transfer or by injection. In the latter case, the mixture was introduced in a 5 ml syringe and injected by a syringe pusher (Harvard 1 1 ) at a velocity of 45 ml /hr. The needle (18 Gauge) was completely immerged in paraffin oil. Particles were recovered by sedimentation in water, sieved (mesh sizes: 150, 355, 425 and 710 microns) and washed to remove salts, traces of oil and epichlorohydrin. Drained particles fractions were weighed to calculated yield.
  • the coated PLA or PLGA particles can be suspended in NaOH (1 N) solution and incubated at 37°C for 24 to 96 hours. Particles are collected, sieved and washed in MilliporeTM water before further use (fraction 425 to 710 microns retained for analysis).
  • Microphotographs were recorded with digital camera using Northern Eclipse software and analyzed for particle size with Optimas (v6.0) image analysis software and examined for morphology by visual inspection. Scanning electron microscopy
  • Control particles and final hollow particles fractions were examined on a JeolTM scanning electron microscope.
  • Fluorescein isothiocyanate Dextrans (FITC-Dextrans) were introduced in polyester core particles as an emulsion. 50 ⁇ l of a FITC-Dextrans aqueous solution was added to the polyester/chloroform mixture, sonicated for 20 seconds on a 550 Sonic DismenbranorTM (Fisher). This primary emulsion was then transferred in a 250 ml 0,3% PVA under stirring (see section annotated Preparation of PLA and PLGA core particle). The ratio of polyester/FITC- Dextrans was about 1 mg to 500 mg, except for batch PLE034: 10 mg to 500mg.
  • microparticles were incubated in NaOH (1 N) solution at 37°C, and examined under microscope, on a Zeiss Axiovert S100TM microscope (Zeiss, Germany), which was equipped with a set of emission/excitation filters (excitation: 495nm, emission 517nm) and a fluorescence lamp. Digital pictures were recorded with a digital camera and use of Northern Eclipse software was also made.
  • the 425 to 710 micron fraction of coated particle batch PLE020 was incubated in NaOH (1 N) solution for 72 hours at 37°C to selectively degrade the core particles. After sieving and repeatedly washing, 500mg of the fraction was re-suspended in 1 ml of H 2 0 containing the fluorescent probe (FITC-Dextrans, 4kD, 10kD or 70 kD) and incubated at room temperature. Aliquots of 10 ⁇ l were collected and analyzed on a spectro- fluorometer. A control assay containing 1 ,5ml of H 2 O with the same quantity of fluorescent probe was also incubated in the same conditions.
  • FITC-Dextrans fluorescent probe
  • Fluorescence diffusion results were expressed as a percentage of the control at each time point in time for each of the FITC Dextrans tested. Similar experiments were simultaneously conducted and particles were observed under fluorescence on a Zeiss Axiovert S100 microscope (Zeiss, Germany) equipped with a set of emission/excitation filters and a fluorescence lamp. Pictures were recorded with a digital camera and use was made to Northern Eclipse software.
  • Amylopectin core particle preparation and coating Assays with amylopectin core particles Amylopectin core particle preparation and coating.
  • an amylopectin particle crosslinked with a crosslinking agent such as trimetaphosphate (TMP), also referred to as AP/TMP particle were prepared to be used as "template” or "core” particle, according to the preparation scheme represented in Figure 1 .
  • TMP crosslinked amylopectin (AP) matrix is very sensitive to basic conditions. To illustrate this point a AP/TMP particle of about 500 microns is completely degraded in NaOH (1 N) in less than 2 hours at room temperature.
  • an epichlorohydrin crosslinked amylopectin matrix is much more resistant to basic conditions. Coating of the core AP/TMP particle by emulsion polymerization with an amylopectin/epichlorohydrin gel gave good results. This result is shown in Figure 2B.
  • the size of the core particle must correspond to the size of the cavity expected, for example around 300 microns for assays of amylopectin/TMP core particles (see Figure 2).
  • PLA or PLGA particles were prepared according to the solvent emulsion/evaporation technique described in the Journal of Controlled Release, 17, (1 991 ), pp. 1 to 22 (Arshady, R.), to produce large particles of about 350 microns.
  • the coating of polyester core particles was first carried out by using the same protocol developed to coat amylopectin/TMP core particles.
  • the thickness of the coating was then determined to be about 500 nm to 500 microns to compromise between mechanical stability and mass transfer of various compounds such as nutriments, reactive substances, secreted substances, enzymes, drugs, genetic material, etc.
  • Coating was carried out by an emulsion polymerization of a solution of amylopectin and polyester core particles in paraffin oil under stirring.
  • the coating was stabilized by an epichlorohydrin crosslinking reaction described in Starch, 37, (1985), pp. 297-306 (Kartha et al.). Although some coated polyester particles were obtained in the initial experiments, the yield is very low. The results can be seen in Figure 3. As a result, there was formation of big lumps composed of polyester particles embedded in an amylopectin matrix.
  • the cavities thus obtained were larger than the core polyester particles. This phenomenon can be explained by a partial degradation of the polyester template particle when it is in contact with the strongly basic amylopectin gel and/or mechanical action of the particle under stirring and/or swelling of the capsule under washing at the end of the process. Similar results are also obtained with PLA core particles (data not shown).
  • Polyester particles are degradable in both acidic and basic conditions. Preliminary experiments on uncoated polyester particles confirm that basic conditions are the fastest. This has been confirmed by a scientific article published in the Journal of Microencapsulation, 3, (1986), pp. 203-212 (Makino et al.). It has been further reported that reactions conducted in basic conditions at 37°C are at least two times faster than those conducted at room temperature. Degradation of PLA particles are 4 to 5 times slower than PLGA (Resomer RG 504HTM) particles (data not shown). The coating of the core particle does not affect the extent of the degradation. The end result, as shown in Figure 3, shows hollow particles with residual polyesters after 6 hours for PLGA and 48 hours for PLA.
  • the preliminary experiments also confirm the feasibility in preparing hollow particles by this method and point out the parameters to be optimized, such parameters including core particle size, selective polyester hydrolysis and core particle coating reaction.
  • the Applicant was able to identify the main factors affecting the efficiency of the polyester core particle coating. These factors may include: stability of emulsion in paraffin oil, stirring speed, geometry of mixer, viscosity of amylopectin mixture, interaction between the polyester's surface and the amylopectin mixture. It is worth mentioning that PLA, as choice of polymer for the core particle preparation was done in an attempt to reduce the cost of future preparations.
  • polyethylene glycol distearate can preferably used as a surface modifier.
  • PEGDS is composed of two stearate moieties at each of its extremities and contains a spacer of PEG (Mn around 930).
  • the surface modifier could also have different properties according to its density. It has further been documented in the International Journal of Pharmaceutics, 174, (1 998), pp. 101 -109 (Lacasse et al.) that a 0,1 % concentration of PEGDS inhibits polyester particle adhesion to macrophage but not 1 %.
  • the initial viscosity is the main factor to influence the coating yield, not the surface modifier as seen in Figure 5C.
  • the viscosity of the mixture is the function of not only the water content but also of the extent of the reaction of epichlorohydrin, primarily governed by the incubation duration and the incubation temperature. These parameters are likely to influence not only the coating yield but also the permeability properties the gel capsule walls.
  • the core particle must have the same diameter as the cavity to be formed, i.e. preferably about 1 to 500 microns.
  • the core particle must have the same diameter as the cavity to be formed, i.e. preferably about 1 to 500 microns.
  • particle sizes of about 175 to 200 microns is the ideal size for cell encapsulation applications only, as cavity diameters are around twice the core particle diameter, as seen in Figures 3 and 4.
  • Core particle synthesis was adapted accordingly.
  • the main parameters to be adjusted were the viscosity of the starting polyester/organic solvent solution and the stirring speed of the emulsion.
  • Sizes of the particles were assessed with Optimas ® image analysis software, Area Equivalent Diameters and Ferret diameters measured gave typical results of 190 ⁇ m with a standard deviation (SD) of + /- 35 ⁇ m after optimization of the parameters such as viscosity, stirring speed and PVA %.
  • SD standard deviation
  • polyester particles are not dried; instead they are just washed and sieved before use. Dried particles are rapidly degraded when , in direct contact with strongly basic amylopectin/epichlorohydrin reaction mix. Observation of PLA particles in the amylopectin mixture before crosslinking occurs, show a thin layer of water around each PLA particle (see Figure 6B), unlike the amylopectin gel particle in the same situation (see Figure 6A). It is further shown that the surface of polyester particles has at least some affinity for water. This phenomenon can also be attributed to residual PVA molecules adsorbed on the particle surface. The water layer acts as a shield between the polyester and the basic solution (NaOH 2N).
  • polyester particles containing FITC-Dextrans 70kD (batch PL034) and as can be seen when comparing Figures 6B and 6C, fluorescence can be observed in the water layer surrounding the particles. This could be explained by the segregation of hydrophilic molecules at the surface of the particle as already observed with PEG (see the International Journal of Pharmaceutics, 174, (1998), pp. 101 -109 (Lacasse et al. 1998)). Also, one can expect some polyester hydrolysis at the surface of the particle; the latter inducing release of some fluorescence in the water layer. The presence of this water layer and possible surface erosion of core particle could contribute to the size of cavities observed relative to core polyester particle diameter, as seen in Figures 3 and 5. Optimization of selective degradation
  • the so formed polyester core particles are very compact, and such can be attributed to the high viscosity of the initial polyester/chloroform mix.
  • the choice to use PLA instead of PLGA increases the incubation time necessary to completely degrade the core particle. The latter can take up to 96 hours for PLA.
  • optimization will need to be carried out. Methods such as double emulsion to weaken polyester particle structure and a choice of a PLA with lower molecular weight should be considered, as per the Journal of Controlled Release, 30, (1994), pp. 161 -173 (Park, T.G.).
  • the hydrated particles were examined by scanning electron microscopy at room temperature and under vacuum. Unlike frozen samples, the amylopectin gel undergoes dehydration over time and eventually collapses in these conditions.
  • Control particles made of crosslinked amylopectin (non hollow particles), were first examined (see Figure 7). As seen in Figure 7A', the pictures taken in the initial moments show a smooth surface for native particles. Fractions with hollow particles were then analyzed, before and after polyester core particle hydrolysis. Upon inspection of Figure 7B', one can observe particles at the initial moment that appear like a deflated balloon.
  • the concentration in the external medium remained at a plateau signifying little or no PLEO23 and/or PLE020 diffusion into the particles as expected.
  • 4kD and 10kD markers showed decrease in fluorescence, but slower than expected.
  • the value of fluorescence is greater than the expected value, and such varies between batches.
  • One explanation could be attributed to insufficient washing of particles after incubation in basic conditions. Indeed, it has been shown that the release of NaOH in the medium can affect the intensity of fluorescence (see Methods in Enzymology, 174, (1989), pp. 131 -145 (Ohkuma, S.)). This could also account for the initial burst of fluorescence seen in the first 30 minutes.
  • Permeability porosity & diffusion. Permeability and/or porosity of the capsule to proteins are essential characteristics of the microcapsules. One can expect that the control of the porosity will be an important concern for regulatory agencies to allow clinical trials.
  • capsule gel permeation The principles governing capsule gel permeation are similar to those of size-exclusion chromatography.
  • the ability of a protein to cross the capsule wall depends on gel pore size, size and shape of the protein and interactions between the protein and the gel network (ionic or hydrophobic).
  • Molecular weight cut-off determination using FITC-Dextrans has to be cautiously interpreted as gel permeability is not directly dependent on molecular weight (Mw), but rather on physical size and shape of the molecule.
  • Mw molecular weight
  • R ⁇ viscosity radius
  • the novel method for preparing microcapsules thus produces particles with a range of permeability characteristics in accordance with immuno- isolation parameters.
  • the microcapsules obtained by the method according to the present invention can be used as a micro-reactor.
  • several substances can be loaded in different core particles.
  • one batch is prepared with PLA microspheres containing FeSO4.
  • a second batch can be prepared with PLA to yield PLA microspheres containing sodium nitrite.
  • a microcapsule could include particles from the first and second batch. In this case there is no need of degrading the polyester core.
  • a slow diffusion of both reactive in the medium allows the reaction and generates nitrogen monoxide (NO) .
  • the microcapsule thus acts as a micro-reactor thereby slowly generating NO by a constant rate through the hydrogel.
  • the microcapsules obtained by the method according to the present invention are to be used as a multi-compartmental drug carrier, several substances can be loaded into the core particles.
  • one batch can be prepared with PLA microspheres containing anti-inflammatory drugs, while a second batch is prepared with PLA to yield PLA microspheres containing an opioid drug.
  • the microcapsules could include particles obtained from both the first and second batches.
  • the cores could be degraded or not.
  • the microcapsules obtained by the method according to the present invention can also be used as a micro-reservoir drug delivery system.
  • one substance can be loaded into the core microsphere, and the particle can then be coated with the hydrogel.
  • the core is then degraded.
  • the drug is free inside the cavity and can be released by diffusion through the gel at a constant rate.
  • An example of such an application can be for example the use of an anticancer drug for brain delivery.
  • the novel method of preparing permeable and sized microcapsules as set forth in the present application is successful. Morphology, size and porosity of the particles can be adjusted. This novel method can be extended to other materials for core particle preparation and coating. Indeed, the use of a wide variety of polymeric degradable core materials can be used; and thus allow for selective degradation in acidic conditions, for example by using polyorthoester polymers.
  • the coating can then preferably be done with trimetaphosphate (TMP) as choice of crosslinking agent, which produce links that are sensitive to basic conditions, but less sensitive to acidic conditions.
  • TMP trimetaphosphate
  • the advantage of TMP as choice of cross-linking agent is considered to be more acceptable in terms of toxicity.
  • Coating can also be done with other natural or synthetic hydrogel and crosslinking methods.
  • the method according to the present invention could also be useful to create multi- compartmental drug delivery devices, wherein a drug can be trapped in the polyester hydrophobic medium, then released during degradation at physiologic pH while the hydrophilic coating can be involved in hydrophilic drug storage, release regulation and biocompatibility of the devices.

Abstract

L'invention porte sur un procédé de préparation de microcapsules perméables et calibrées à capacité de transfert de masse appropriée. Ledit procédé comporte les étapes suivantes: a) préparation de particules de polymère dégradable facultativement chargées par un ingrédient actif; b) enduction par émulsion polymérisation desdites particules au moyen d'un mélange enrobant de l'épaisseur désirée; et c) dégradation sélective de la particule enduite dans des conditions acides ou basiques par variation du pH et/ou dégradation hydrolytique, pour y former au moins une cavité. L'invention porte également sur des microcapsules perméables et calibrées à capacité de transfert de masse appropriée obtenues par ledit procédé, et sur l'utilisation desdites microcapsules.
PCT/CA2004/000803 2003-05-28 2004-05-28 Procede de preparation de microcapsules WO2004105734A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47347703P 2003-05-28 2003-05-28
US60/473,477 2003-05-28

Publications (1)

Publication Number Publication Date
WO2004105734A1 true WO2004105734A1 (fr) 2004-12-09

Family

ID=33490609

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/000803 WO2004105734A1 (fr) 2003-05-28 2004-05-28 Procede de preparation de microcapsules

Country Status (1)

Country Link
WO (1) WO2004105734A1 (fr)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010046286A1 (fr) * 2008-10-24 2010-04-29 Basf Se Procédé de fabrication de microparticules contenant une substance active
US8263327B2 (en) 2007-04-26 2012-09-11 Basf Se Enzymatic method for the production of microcapsules
US9388465B2 (en) 2013-02-08 2016-07-12 10X Genomics, Inc. Polynucleotide barcode generation
US9410201B2 (en) 2012-12-14 2016-08-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9689024B2 (en) 2012-08-14 2017-06-27 10X Genomics, Inc. Methods for droplet-based sample preparation
US9694361B2 (en) 2014-04-10 2017-07-04 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9824068B2 (en) 2013-12-16 2017-11-21 10X Genomics, Inc. Methods and apparatus for sorting data
US9885034B2 (en) 2011-04-25 2018-02-06 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10085946B2 (en) 2012-09-04 2018-10-02 Technion Research & Development Foundation Limited Use of decellularized extracellular matrix for encapsulating cells
WO2019040355A1 (fr) * 2017-08-21 2019-02-28 President And Fellows Of Harvard College Microcapsules de poly(acide) et procédés associés
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US10221436B2 (en) 2015-01-12 2019-03-05 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10287623B2 (en) 2014-10-29 2019-05-14 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10395758B2 (en) 2013-08-30 2019-08-27 10X Genomics, Inc. Sequencing methods
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10428326B2 (en) 2017-01-30 2019-10-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US10471016B2 (en) 2013-11-08 2019-11-12 President And Fellows Of Harvard College Microparticles, methods for their preparation and use
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10650912B2 (en) 2015-01-13 2020-05-12 10X Genomics, Inc. Systems and methods for visualizing structural variation and phasing information
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10774370B2 (en) 2015-12-04 2020-09-15 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US10839939B2 (en) 2014-06-26 2020-11-17 10X Genomics, Inc. Processes and systems for nucleic acid sequence assembly
US10854315B2 (en) 2015-02-09 2020-12-01 10X Genomics, Inc. Systems and methods for determining structural variation and phasing using variant call data
US11081208B2 (en) 2016-02-11 2021-08-03 10X Genomics, Inc. Systems, methods, and media for de novo assembly of whole genome sequence data
US11084036B2 (en) 2016-05-13 2021-08-10 10X Genomics, Inc. Microfluidic systems and methods of use
US11123297B2 (en) 2015-10-13 2021-09-21 President And Fellows Of Harvard College Systems and methods for making and using gel microspheres
US11155881B2 (en) 2018-04-06 2021-10-26 10X Genomics, Inc. Systems and methods for quality control in single cell processing
CN113711012A (zh) * 2018-09-14 2021-11-26 联合利华知识产权控股有限公司 免洗型化妆品组合物保护皮肤免受污染的功效的评估
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
US11401550B2 (en) 2008-09-19 2022-08-02 President And Fellows Of Harvard College Creation of libraries of droplets and related species
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US11629344B2 (en) 2014-06-26 2023-04-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11773389B2 (en) 2017-05-26 2023-10-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11898206B2 (en) 2017-05-19 2024-02-13 10X Genomics, Inc. Systems and methods for clonotype screening

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005943A1 (fr) * 2000-07-17 2002-01-24 Kappa Biotech S.A. Procede et dispositif de fabrication de particules polymeriques creuses contenant des substances d'interet

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005943A1 (fr) * 2000-07-17 2002-01-24 Kappa Biotech S.A. Procede et dispositif de fabrication de particules polymeriques creuses contenant des substances d'interet

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CROTTS G ET AL: "Preparation of porous and nonporous biodegradable polymeric hollow microspheres", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 35, no. 2, 1 August 1995 (1995-08-01), pages 91 - 105, XP004037480, ISSN: 0168-3659 *
JOSEPH N J ET AL: "A floating-type oral dosage form for piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo evaluation in rabbits", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 79, no. 1-3, 19 February 2002 (2002-02-19), pages 71 - 79, XP004340913, ISSN: 0168-3659 *
KAWASHIMA Y ET AL: "PREPARATION OF MULTIPLE UNIT HOLLOW MICROSPHERES (MICROBALLOONS) WITH ACRYLIC RESIN CONTAINING TRANILAST AND THEIR DRUG RELEASE CHARACTERISTICS (IN VITRO) AND FLOATING BEHAVIOR (IN VIVO)", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 16, no. 3, 1 August 1991 (1991-08-01), pages 279 - 289, XP000223715, ISSN: 0168-3659 *

Cited By (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263327B2 (en) 2007-04-26 2012-09-11 Basf Se Enzymatic method for the production of microcapsules
US11401550B2 (en) 2008-09-19 2022-08-02 President And Fellows Of Harvard College Creation of libraries of droplets and related species
WO2010046286A1 (fr) * 2008-10-24 2010-04-29 Basf Se Procédé de fabrication de microparticules contenant une substance active
US11939573B2 (en) 2011-04-25 2024-03-26 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US9885034B2 (en) 2011-04-25 2018-02-06 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US10760073B2 (en) 2011-04-25 2020-09-01 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US10190115B2 (en) 2011-04-25 2019-01-29 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US10626458B2 (en) 2012-08-14 2020-04-21 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10597718B2 (en) 2012-08-14 2020-03-24 10X Genomics, Inc. Methods and systems for sample processing polynucleotides
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US9689024B2 (en) 2012-08-14 2017-06-27 10X Genomics, Inc. Methods for droplet-based sample preparation
US11441179B2 (en) 2012-08-14 2022-09-13 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11021749B2 (en) 2012-08-14 2021-06-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11359239B2 (en) 2012-08-14 2022-06-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11035002B2 (en) 2012-08-14 2021-06-15 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9695468B2 (en) 2012-08-14 2017-07-04 10X Genomics, Inc. Methods for droplet-based sample preparation
US11078522B2 (en) 2012-08-14 2021-08-03 10X Genomics, Inc. Capsule array devices and methods of use
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10053723B2 (en) 2012-08-14 2018-08-21 10X Genomics, Inc. Capsule array devices and methods of use
US10450607B2 (en) 2012-08-14 2019-10-22 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10669583B2 (en) 2012-08-14 2020-06-02 10X Genomics, Inc. Method and systems for processing polynucleotides
US10752950B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10434068B2 (en) 2012-09-04 2019-10-08 Technion Research & Development Foundation Limited Use of decellularized extracellular matrix for encapsulating cells
US10085946B2 (en) 2012-09-04 2018-10-02 Technion Research & Development Foundation Limited Use of decellularized extracellular matrix for encapsulating cells
US10676789B2 (en) 2012-12-14 2020-06-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10253364B2 (en) 2012-12-14 2019-04-09 10X Genomics, Inc. Method and systems for processing polynucleotides
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9410201B2 (en) 2012-12-14 2016-08-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11473138B2 (en) 2012-12-14 2022-10-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9856530B2 (en) 2012-12-14 2018-01-02 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11421274B2 (en) 2012-12-14 2022-08-23 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10612090B2 (en) 2012-12-14 2020-04-07 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9567631B2 (en) 2012-12-14 2017-02-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10227648B2 (en) 2012-12-14 2019-03-12 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9388465B2 (en) 2013-02-08 2016-07-12 10X Genomics, Inc. Polynucleotide barcode generation
US10150964B2 (en) 2013-02-08 2018-12-11 10X Genomics, Inc. Partitioning and processing of analytes and other species
US10150963B2 (en) 2013-02-08 2018-12-11 10X Genomics, Inc. Partitioning and processing of analytes and other species
US9644204B2 (en) 2013-02-08 2017-05-09 10X Genomics, Inc. Partitioning and processing of analytes and other species
US11193121B2 (en) 2013-02-08 2021-12-07 10X Genomics, Inc. Partitioning and processing of analytes and other species
US10395758B2 (en) 2013-08-30 2019-08-27 10X Genomics, Inc. Sequencing methods
US10471016B2 (en) 2013-11-08 2019-11-12 President And Fellows Of Harvard College Microparticles, methods for their preparation and use
US9824068B2 (en) 2013-12-16 2017-11-21 10X Genomics, Inc. Methods and apparatus for sorting data
US10343166B2 (en) 2014-04-10 2019-07-09 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US9694361B2 (en) 2014-04-10 2017-07-04 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10150117B2 (en) 2014-04-10 2018-12-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10137449B2 (en) 2014-04-10 2018-11-27 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10071377B2 (en) 2014-04-10 2018-09-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10208343B2 (en) 2014-06-26 2019-02-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11629344B2 (en) 2014-06-26 2023-04-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10337061B2 (en) 2014-06-26 2019-07-02 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11713457B2 (en) 2014-06-26 2023-08-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10480028B2 (en) 2014-06-26 2019-11-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10457986B2 (en) 2014-06-26 2019-10-29 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10839939B2 (en) 2014-06-26 2020-11-17 10X Genomics, Inc. Processes and systems for nucleic acid sequence assembly
US10030267B2 (en) 2014-06-26 2018-07-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10041116B2 (en) 2014-06-26 2018-08-07 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11133084B2 (en) 2014-06-26 2021-09-28 10X Genomics, Inc. Systems and methods for nucleic acid sequence assembly
US10344329B2 (en) 2014-06-26 2019-07-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10760124B2 (en) 2014-06-26 2020-09-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10287623B2 (en) 2014-10-29 2019-05-14 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US11739368B2 (en) 2014-10-29 2023-08-29 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US11135584B2 (en) 2014-11-05 2021-10-05 10X Genomics, Inc. Instrument systems for integrated sample processing
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
US10245587B2 (en) 2014-11-05 2019-04-02 10X Genomics, Inc. Instrument systems for integrated sample processing
US11414688B2 (en) 2015-01-12 2022-08-16 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10221436B2 (en) 2015-01-12 2019-03-05 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10557158B2 (en) 2015-01-12 2020-02-11 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10650912B2 (en) 2015-01-13 2020-05-12 10X Genomics, Inc. Systems and methods for visualizing structural variation and phasing information
US10854315B2 (en) 2015-02-09 2020-12-01 10X Genomics, Inc. Systems and methods for determining structural variation and phasing using variant call data
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
US11603554B2 (en) 2015-02-24 2023-03-14 10X Genomics, Inc. Partition processing methods and systems
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
US11123297B2 (en) 2015-10-13 2021-09-21 President And Fellows Of Harvard College Systems and methods for making and using gel microspheres
US10774370B2 (en) 2015-12-04 2020-09-15 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11624085B2 (en) 2015-12-04 2023-04-11 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11473125B2 (en) 2015-12-04 2022-10-18 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11873528B2 (en) 2015-12-04 2024-01-16 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11081208B2 (en) 2016-02-11 2021-08-03 10X Genomics, Inc. Systems, methods, and media for de novo assembly of whole genome sequence data
US11084036B2 (en) 2016-05-13 2021-08-10 10X Genomics, Inc. Microfluidic systems and methods of use
US10480029B2 (en) 2016-12-22 2019-11-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11180805B2 (en) 2016-12-22 2021-11-23 10X Genomics, Inc Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10858702B2 (en) 2016-12-22 2020-12-08 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323278B2 (en) 2016-12-22 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10793905B2 (en) 2016-12-22 2020-10-06 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10428326B2 (en) 2017-01-30 2019-10-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US11193122B2 (en) 2017-01-30 2021-12-07 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US11898206B2 (en) 2017-05-19 2024-02-13 10X Genomics, Inc. Systems and methods for clonotype screening
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11198866B2 (en) 2017-05-26 2021-12-14 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10844372B2 (en) 2017-05-26 2020-11-24 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11155810B2 (en) 2017-05-26 2021-10-26 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10927370B2 (en) 2017-05-26 2021-02-23 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11773389B2 (en) 2017-05-26 2023-10-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
WO2019040355A1 (fr) * 2017-08-21 2019-02-28 President And Fellows Of Harvard College Microcapsules de poly(acide) et procédés associés
US10876147B2 (en) 2017-11-15 2020-12-29 10X Genomics, Inc. Functionalized gel beads
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US11884962B2 (en) 2017-11-15 2024-01-30 10X Genomics, Inc. Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US11155881B2 (en) 2018-04-06 2021-10-26 10X Genomics, Inc. Systems and methods for quality control in single cell processing
CN113711012A (zh) * 2018-09-14 2021-11-26 联合利华知识产权控股有限公司 免洗型化妆品组合物保护皮肤免受污染的功效的评估

Similar Documents

Publication Publication Date Title
WO2004105734A1 (fr) Procede de preparation de microcapsules
JP2711231B2 (ja) タンパク質マイクロスフェアを生産する方法
Parakhonskiy et al. Colloidal micro-and nano-particles as templates for polyelectrolyte multilayer capsules
US6706288B2 (en) Microparticles
Lim et al. Particle designs for the stabilization and controlled-delivery of protein drugs by biopolymers: a case study on insulin
US4532123A (en) Dual Microcapsules and process for their preparation
Abdelkader et al. Review on micro-encapsulation with chitosan for pharmaceuticals applications
CA1204058A (fr) Microcapsules doubles
JP2003522781A (ja) コロイド系を含むミクロスフェアの調製のための方法
AU1186401A (en) Ionically formulated biomolecule microcarriers
Liu et al. Immobilization and bioactivity of glucose oxidase in hydrogel microspheres formulated by an emulsification–internal gelation–adsorption–polyelectrolyte coating method
JP2004521152A (ja) 生分解ポリマーを基にした材料及びその製造方法
WO2000064954A1 (fr) Systeme d'encapsulation de polymeres facilitant l'angiogenese
JPH08509246A (ja) エステル化した多糖類とポリアミン化またはポリヒドロキシル化した物質の間のトランスアシル化反応の微粒子製造への使用、そのようにして製造された微粒子、方法、およびそれを含有する組成物
KR20030051687A (ko) 분자량이 감소된 정제 아밀로펙틴-기제 녹말을 갖는서방투여용 생분해성 미세입자
AU2001294458A1 (en) Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight
EP1021168A1 (fr) Dispositif d'administration de microparticules ou de nanoparticules de polymeres
EP2176321A2 (fr) Particules poreuses de polymère comprenant des molécules chargées immobilisées et procédé servant à préparer celles-ci
Rabanel et al. Preparation of hydrogel hollow particles for cell encapsulation by a method of polyester core degradation
Chen et al. Genipin cross-linked polymeric alginate-chitosan microcapsules for oral delivery: in-vitro analysis
US20040115281A1 (en) Microparticles
Levy et al. Mixed-walled microcapsules made of cross-linked proteins and polysaccharides: preparation and properties
Srivastava et al. Application of self-assembled ultra-thin film coatings to stabilize macromolecule encapsulation in alginate microspheres
WO1988000237A1 (fr) Membranes covalentes
CN114288262B (zh) 一种载药微球及其制备方法和应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase